Lobe Sciences Ltd.
LOBEF
$0.08
-$0.01-6.21%
OTC PK
| 02/28/2026 | 11/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | 174.60% | -69.57% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 68.59% | -22.94% | |||
| Operating Income | -68.59% | 22.94% | |||
| Income Before Tax | -87.21% | 42.28% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -87.21% | 42.28% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 58.90% | 35.03% | |||
| Net Income | -99.28% | 53.59% | |||
| EBIT | -68.59% | 22.94% | |||
| EBITDA | -- | -- | |||
| EPS Basic | -96.00% | 99.65% | |||
| Normalized Basic EPS | -118.18% | 99.76% | |||
| EPS Diluted | -96.00% | 99.65% | |||
| Normalized Diluted EPS | -118.18% | 99.76% | |||
| Average Basic Shares Outstanding | 0.86% | 13,431.82% | |||
| Average Diluted Shares Outstanding | 0.86% | 13,431.82% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||